These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 31335485)
1. Surrogate Molecular Classification of Invasive Breast Carcinoma: A Comparison Between Core Needle Biopsy and Surgical Excision, With and Without Neoadjuvant Therapy. Ambrosini-Spaltro A; Zunarelli E; Bettelli S; Lupi M; Bernardelli G; Milani M; Ficarra G Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):551-557. PubMed ID: 31335485 [TBL] [Abstract][Full Text] [Related]
2. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer. Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986 [TBL] [Abstract][Full Text] [Related]
3. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. Chen X; Sun L; Mao Y; Zhu S; Wu J; Huang O; Li Y; Chen W; Wang J; Yuan Y; Fei X; Jin X; Shen K BMC Cancer; 2013 Aug; 13():390. PubMed ID: 23957561 [TBL] [Abstract][Full Text] [Related]
4. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature. Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196 [TBL] [Abstract][Full Text] [Related]
5. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. Robertson S; Rönnlund C; de Boniface J; Hartman J Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433 [TBL] [Abstract][Full Text] [Related]
6. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283 [TBL] [Abstract][Full Text] [Related]
7. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer. Asogan AB; Hong GS; Arni Prabhakaran SK Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805 [TBL] [Abstract][Full Text] [Related]
8. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Chen X; Yuan Y; Gu Z; Shen K Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627 [TBL] [Abstract][Full Text] [Related]
9. Concordance of immunohistochemistry between core needle biopsy and surgical resection of breast cancer. Kombak FE; Şahin H; Mollamemişoğlu H; Önem İ; Kaya H; Buğdaycı O; Arıbal E Turk J Med Sci; 2017 Dec; 47(6):1791-1796. PubMed ID: 29306240 [TBL] [Abstract][Full Text] [Related]
10. Effect of neoadjuvant therapy on breast cancer biomarker profile. Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413 [TBL] [Abstract][Full Text] [Related]
11. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007 [TBL] [Abstract][Full Text] [Related]
12. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication. Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212 [TBL] [Abstract][Full Text] [Related]
13. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747 [TBL] [Abstract][Full Text] [Related]
14. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Maisonneuve P; Disalvatore D; Rotmensz N; Curigliano G; Colleoni M; Dellapasqua S; Pruneri G; Mastropasqua MG; Luini A; Bassi F; Pagani G; Viale G; Goldhirsch A Breast Cancer Res; 2014 Jun; 16(3):R65. PubMed ID: 24951027 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers. Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989 [TBL] [Abstract][Full Text] [Related]
16. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors. Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051 [TBL] [Abstract][Full Text] [Related]
17. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205 [TBL] [Abstract][Full Text] [Related]
18. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy. Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461 [TBL] [Abstract][Full Text] [Related]
19. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist. Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM Histopathology; 2024 Sep; 85(3):437-450. PubMed ID: 38651302 [TBL] [Abstract][Full Text] [Related]
20. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M; Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]